Abstract
Introduction: Sorafenib is the standard care for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT), though it offers limited survival. This study was designed to compare clinical outcomes between liver resection (surgery) and transarterial chemoembolization plus radiotherapy (TACE-RT) as the initial treatment modality for resectable treatment-naïve solitary HCC combined with subsegmental (Vp1), segmental (Vp2), and lobar (Vp3) PVTT. Methods: From the institutional HCC registry, we identified 116 patients diagnosed with resectable treatment-naïve HCC with Vp1–Vp3 PVTT based on radiologic images who received surgery (n = 44) or TACE-RT (n = 72) as a primary treatment between 2010 and 2015. A propensity score matching (PSM) model was created. Results: The TACE-RT group had a higher tumor burden (tumor size, extent, and markers) than the surgery group. Cumulative patient survival curve in the surgery group was significantly higher than that in the TACE-RT group before and after PSM. Liver function was relatively well preserved in the surgery group compared with the TACE-RT group. TACE-RT group, male, increased alkaline phosphatase, and increased platelet count were predisposing factors for patient death in resectable treatment-naïve solitary HCC with PVTT. Discussion/Conclusion: The present study suggests that surgery is considered as an initial treatment in selectively resectable treatment-naïve solitary HCC with Vp1–Vp3 PVTT.
References
1.
Cabibbo
G
, Enea
M
, Attanasio
M
, Bruix
J
, Craxì
A
, Cammà
C
. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma
. Hepatology
. 2010
;51
(4
):1274
–83
. .2.
Korean Liver Cancer
A
, National Cancer
C
. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma
. Gut Liver
. 2018
;13
(3
):227
–99
. .3.
Heimbach
JK
, Kulik
LM
, Finn
RS
, Sirlin
CB
, Abecassis
MM
, Roberts
LR
, Aasld guidelines for the treatment of hepatocellular carcinoma
. Hepatology
. 2018
;67
(1
):358
–80
.4.
European Association for the Study of the Liver
. EASL clinical practice guidelines: management of hepatocellular carcinoma
. J Hepatol
. 2018
;69
(1
):182
–236
.5.
Yu
SJ
. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016
. Clin Mol Hepatol
. 2016
;22
(1
):7
–17
. .6.
Yu
JI
, Park
HC
. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
. World J Gastroenterol
. 2016
;22
(30
):6851
–63
. .7.
Yu
JI
, Park
JW
, Park
HC
, Yoon
SM
, Lim
DH
, Lee
JH
, Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: an external validation study
. Radiother Oncol
. 2016
;118
(2
):408
–15
.8.
Yoon
SM
, Ryoo
BY
, Lee
SJ
, Kim
JH
, Shin
JH
, An
JH
, Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial
. JAMA Oncol
. 2018
;4
(5
):661
–9
.9.
Kokudo
T
, Hasegawa
K
, Matsuyama
Y
, Takayama
T
, Izumi
N
, Kadoya
M
, Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion
. J Hepatol
. 2016
;65
(5
):938
–43
.10.
Kim
JM
, Kwon
CH
, Joh
JW
, Ko
JS
, Park
JB
, Lee
JH
, C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion
. World J Surg Oncol
. 2013
;11
:92
.11.
Sinn
DH
, Lee
HW
, Paik
YH
, Kim
DY
, Kim
YJ
, Kim
KM
, Patterns and outcomes in hepatocellular carcinoma patients with portal vein invasion: a multicenter prospective cohort study
. Dig Dis Sci
. 2021
;66
(1
):315
–24
.12.
Shi
J
, Lai
EC
, Li
N
, Guo
WX
, Xue
J
, Lau
WY
, A new classification for hepatocellular carcinoma with portal vein tumor thrombus
. J Hepatobiliary Pancreat Sci
. 2011
;18
(1
):74
–80
.13.
Kim
JM
, Kwon
CH
, Joh
JW
, Park
JB
, Lee
JH
, Kim
SJ
, Outcomes after curative hepatectomy in patients with non-b non-c hepatocellular carcinoma and hepatitis b virus hepatocellular carcinoma from non-cirrhotic liver
. J Surg Oncol
. 2014
;110
(8
):976
–81
.14.
Yu
JI
, Park
HC
, Lim
DH
, Kim
CJ
, Oh
D
, Yoo
BC
, Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma
. J Korean Med Sci
. 2012
;27
(7
):736
–43
.15.
Brookhart
MA
, Schneeweiss
S
, Rothman
KJ
, Glynn
RJ
, Avorn
J
, Stürmer
T
. Variable selection for propensity score models
. Am J Epidemiol
. 2006
;163
(12
):1149
–56
. .16.
Austin
PC
. An introduction to propensity score methods for reducing the effects of confounding in observational studies
. Multivariate Behav Res
. 2011
;46
(3
):399
–424
. .17.
Sinn
DH
, Cho
JY
, Gwak
GY
, Paik
YH
, Choi
MS
, Lee
JH
, Different survival of barcelona clinic liver cancer stage c hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread
. PLoS One
. 2015
;10
(4
):e0124434
.18.
Kudo
M
, Izumi
N
, Kubo
S
, Kokudo
N
, Sakamoto
M
, Shiina
S
, Report of the 20th nationwide follow-up survey of primary liver cancer in japan
. Hepatol Res
. 2020
;50
(1
):15
–46
.19.
Yamamoto
Y
, Ikoma
H
, Morimura
R
, Shoda
K
, Konishi
H
, Murayama
Y
, Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis
. World J Gastroenterol
. 2015
;21
(1
):246
–53
.20.
Nevarez
NM
, Yopp
AC
. Challenging the treatment paradigm: selecting patients for surgical management of hepatocellular carcinoma with portal vein tumor thrombus
. J Hepatocell Carcinoma
. 2021
;8
:851
–60
. .21.
Tang
QH
, Li
AJ
, Yang
GM
, Lai
EC
, Zhou
WP
, Jiang
ZH
, Surgical resection versus conformal radiotherapy combined with tace for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study
. World J Surg
. 2013
;37
(6
):1362
–70
.22.
Lee
CH
, Lee
YB
, Kim
MA
, Jang
H
, Oh
H
, Kim
SW
, Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
. Clin Mol Hepatol
. 2020
;26
(3
):328
–39
.23.
Kim
J
, Jung
Y
. Radiation-induced liver disease: current understanding and future perspectives
. Exp Mol Med
. 2017
;49
(7
):e359
. .24.
Padickakudy
R
, Pereyra
D
, Offensperger
F
, Jonas
P
, Oehlberger
L
, Schwarz
C
, Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans
. J Hepatol
. 2017
;67
(6
):1243
–52
.25.
Aryal
B
, Shimizu
T
, Kadono
J
, Furoi
A
, Komokata
T
, Kitazono
I
, Post-resection exhaustion of intra-platelet serotonin: also an indicator of early hepatocellular carcinoma recurrence?
J Cancer
. 2017
;8
(19
):3984
–91
.26.
Pang
Q
, Qu
K
, Zhang
JY
, Song
SD
, Liu
SS
, Tai
MH
, The prognostic value of platelet count in patients with hepatocellular carcinoma: a systematic review and meta-analysis
. Medicine
. 2015
;94
(37
):e1431
.27.
Zhang
Z
, Zhang
Y
, Wang
W
, Hua
Y
, Liu
L
, Shen
S
, Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis
. J Surg Res
. 2017
;210
:99
–107
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
